Market Analysis: Global Smith-Lemli-Opitz Syndrome Market
Market Definition: Global Smith-Lemli-Opitz Syndrome Market
Smith-Lemli-Opitz Syndrome (SLOS) is also known as Rutledge lethal multiple congenital anomaly syndromes are rare developmental disorder characterized by multiple congenital anomalies, learning problems and behavioral problems. It is caused by mutation in the DHCR7 (7-dehydrocholesterol reductase) gene which codes for an enzyme that is involved in the secretion of cholesterol in the brain. People with Smith-Lemli-Opitz syndrome are unable to make enough cholesterol as they should in the brain to support normal growth and development and eventually leads to develop neuropsychiatric and neurodevelopmental symptoms.
According to the source from National Organization for Rare Disorders, Inc, an estimated annual prevalence of Smith-Lemli-Opitz syndrome is approximately 1 in 20,000 to 60,000 live births in the United States. Presence of refined healthcare infrastructure and high demand of disease specific novel therapies are the key factors that fueling the market growth
Get More Insights About Global Smith-Lemli-Opitz Syndrome Market, Request Sample @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-smith-lemli-opitz-syndrome-market
Huge financial support to the researchers for developing novel intervention is boosting the market growth
High demand of disease specific novel treatment can also act as a market driver
Emergence of drug used in the treatment of complications associated with Smith-Lemli-Opitz syndrome
High unmet need and emerging new market can drive the growth of this market
Limited operating revenue opportunities for research and development of targeted therapies by many pharmaceuticals is acting as a challenging factor for the growth of this market
Low healthcare budget in some developing countries is hamper the market growth
Know more about this report https://www.databridgemarketresearch.com/reports/global-smith-lemli-opitz-syndrome-market
Segmentation: Global Smith-Lemli-Opitz Syndrome Market
Molecular Genetic Testing
HMG CoA Reductase Inhibitor
By Route of Administration
By End Users
By Distribution Channel
Rest of South America
Rest of Europe
Rest of Asia Pacific
Middle East & Africa
Rest of Middle East & Africa
Key Developments in the Market:
In February 2018, according to the news published in Technical Network by Ellen Goldbaum for University at Buffalo that researcher from the Jacobs School of Medicine and Biomedical Sciences at the University at Buffalo and VA Western New York Healthcare System has demonstrated that antioxidant combination therapy resulted in preventing the retinal degeneration that can occur in babies born with Smith-Lemli-Opitz Syndrome (SLOS). This reserach can excite other researcher to further investigate a potential treatment for SLOS patients.
Key Market Players:
Few of the major competitors currently working in the global Smith-Lemli-Opitz syndrome market are Teva Pharmaceutical Industries Ltd, Dr. Reddy’s Laboratories Ltd, Sun Pharmaceutical Industries Ltd, Zydus Cadila, Aurobindo Pharma, LUPIN, Micro Labs Ltd, Hetero, Biocon, Accord Healthcare, Merck & Co., Inc. and others
Demand Side: Doctors, Surgeons, Medical Consultants, Nurses, Hospital Buyers, Group Purchasing Organizations, Associations, Insurers, Medical Payers, Healthcare Authorities, Universities, Technological Writers, Scientists, Promoters, and Investors among others.
Supply Side: Product Managers, Marketing Managers, C-Level Executives, Distributors, Market Intelligence, and Regulatory Affairs Managers among others.
Request for Detailed TOC @ https://www.databridgemarketresearch.com/toc/?dbmr=global-smith-lemli-opitz-syndrome-market
Browse Trending Related Reports @
About Data Bridge Market Research: